Strategies for drug discovery for cognitive aging and alzheimer’s disease Howard M. FillitAlan W. O’ConnellLorenzo M. Refolo Introduction Pages: 1 - 3
Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer’s disease Mei-Ping KungCatherine HouHank F. Kung Early Detection Of Cognitive Impairment Pages: 7 - 10
Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease Yanming WangWilliam E. KlunkChester A. Mathis Early Detection Of Cognitive Impairment Pages: 11 - 16
Brain-imaging surrogate markers for detection and prevention of age-related memory loss Gary W. Small Early Detection Of Cognitive Impairment Pages: 17 - 21
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial Michael GrundmanDrahomira Sencakovathe Alzheimer’s Disease Cooperative Study Early Detection Of Cognitive Impairment Pages: 23 - 27
Lipid rafts play an important role in Aβ biogenesis by regulating the β-secretase pathway Han TunLaura MarlowKumar Sambamurti Target Identification And Validation Pages: 31 - 35
The role of the low-density lipoprotein receptor-related protein (LRP1) in alzheimer’s Aβ generation Joy J. GotoRudolph E. Tanzi Target Identification And Validation Pages: 37 - 41
Novel glycosaminoglycan precursors as anti-amyloid agents part II Robert KisilevskyWalter A. Szarek Lead Compound Discovery And Optimization Pages: 45 - 50
Per-6-substituted β-cyclodextrin libraries inhibit formation of β-amyloid-peptide (Aβ)-derived, soluble oligomers Jiaxin YuLara BakhosDuane L. Venton Lead Compound Discovery And Optimization Pages: 51 - 55
Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death Lee-Way JinDuy H. HuaGeorge M. Martin Lead Compound Discovery And Optimization Pages: 57 - 61
Development of a new treatment for alzheimer’s disease and parkinson’s disease using anti-aggregatory β-synuclein-derived peptides Manfred WindischBirgit Hutter-PaierEliezer Masliah Lead Compound Discovery And Optimization Pages: 63 - 69
Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels Beth M. McMahonJennifer StewartElliott Richelson Lead Compound Discovery And Optimization Pages: 71 - 76
Alzheimer’s disease drug discovery targeted to the APP mRNA 5′Untranslated region Jack T. RogersJeffrey D. RandallSteven R. Gullans Lead Compound Discovery And Optimization Pages: 77 - 82
Continuing strategies for inhibiting alzheimer’s γ-secretase Michael S. WolfeWilliam P. EslerChittaranjan Das Lead Compound Discovery And Optimization Pages: 83 - 87
Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses D. Martin WattersonJacques HaiechLinda J. Van Eldik Lead Compound Discovery And Optimization Pages: 89 - 93
Significance and mechanism of alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion Khalid IqbalAlejandra del C. AlonsoInge Grundke-Iqbal Lead Compound Discovery And Optimization Pages: 95 - 99
Amyloid peptide toxicity and microtubule-stabilizing drugs Mary L. MichaelisYingxue ChenKenneth Audus Lead Compound Discovery And Optimization Pages: 101 - 105
Alzheimer’s therapeutics Stephen M. MassaYoumei XieFrank M. Longo Lead Compound Discovery And Optimization Pages: 107 - 111
Structure-based functional design of chemical ligands for AMPA-subtype glutamate receptors Lei ZengLuying LuMing-Ming Zhou Lead Compound Discovery And Optimization Pages: 113 - 116
Modulation of axonal regeneration in neurodegenerative disease Stephen M. Strittmatter Lead Compound Discovery And Optimization Pages: 117 - 121
Towards a high-affinity allosteric enhancer at muscarinic M1 receptors Sebastian LazarenoAngela PophamNigel J. M. Birdsall Lead Compound Discovery And Optimization Pages: 123 - 127
Natural product extracts that reduce accumulation of the alzheimer’s amyloid β peptide Debra YagerMona WatsonChristopher B. Eckman Lead Compound Discovery And Optimization Pages: 129 - 133
Calpain inhibitors Gabriella Di RosaTatjana OdrlijnOttavio Arancio Lead Compound Discovery And Optimization Pages: 135 - 141
AF150(S) and AF267B Abraham FisherRachel BrandeisZipora Pittel Preclinical Development Pages: 145 - 153
Statin therapy for Alzheimer’s disease Suzana S. PetanceskaSteven DeRosaLorenzo M. Refolo Preclinical Development Pages: 155 - 161
Ovariectomy of young mutant amyloid precursor protein transgenic mice leads to increased mortality Justine A. Levin-AllerhandJonathan D. Smith Preclinical Development Pages: 163 - 166
NAP accelerates the performance of normal rats in the water maze Illana GozesRoy AlcalayDouglas E. Brenneman Preclinical Development Pages: 167 - 170
CREB and the discovery of cognitive enhancers Roderick ScottRusiko BourtchuladzeTim Tully Preclinical Development Pages: 171 - 177
A computer-assisted cognitive test battery for aged monkeys Jerry J. BuccafuscoAlvin V. TerryPaul B. Murdoch Preclinical Development Pages: 179 - 185
The utility of muscarinic agonists in the treatment of alzheimer’s disease William S. Messer Preclinical Development Pages: 187 - 193
Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine® CX516 in elderly participants with mild cognitive impairment Steven A. JohnsonVincent F. Simmon Clinical Drug Development Pages: 197 - 200
Slowing the progression of cognitive decline in alzheimer’s disease using mifepristone Joseph K. BelanoffJennifer JurikAlan F. Schatzberg Clinical Drug Development Pages: 201 - 206
Nerve growth factor gene therapy for alzheimer’s disease Mark H. TuszynskiLeon ThalH. Lee Vahlsing Clinical Drug Development Pages: 207 - 207
Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated? D. Larry SparksDonald J. ConnorBehalf of the AD Cholesterol-Lowering Treatment Trial Team Clinical Drug Development Pages: 209 - 212
Development of indole-3-propionic acid (OXIGON™) for alzheimer’s disease Paul E. BendheimBurkhard PoeggelerDaniel G. Chain Clinical Drug Development Pages: 213 - 217
Estrogen and cognitive functioning in men with mild cognitive impairment Barbara B. Sherwin Clinical Drug Development Pages: 219 - 223
Effects of aerobic fitness training on human cortical function Arthur F. KramerStanley ColcombeTracey M. Wszalek Prevention: Genetics And Risk Factor Pages: 227 - 231
The genetics of exceptional human longevity Thomas PerlsLouis M. KunkelAnnibale A. Puca Prevention: Genetics And Risk Factor Pages: 233 - 238
Genetic and environmental risk factors for alzheimer’s disease in israeli arabs Abdalla BowirratRobert P. FriedlandAmos Korczyn Prevention: Genetics And Risk Factor Pages: 239 - 245